Second Quarter 2023 Earnings

Second Quarter Year-to-Date 2023 Key Financial Metrics (In millions, except percentage data) Reported Revenue Growth Revenue Growth1 GAAP Net Income² Non-GAAP Net Income ³ Excluding KUVANⓇ $1,192 $149 $1,091 $1,053 $936 +13% +16% (-28%) $221 $176 $107 +26% YTD 2023 YTD 2022 Includes total revenues excluding revenues from KUVAN. YTD 2022 1 2 3 8 YTD 2023 YTD 2022 YTD 2023 YTD 2022 YTD 2023 GAAP Net income in the first half of 2022 included a $89.0 million net gain, net of taxes, related to the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the U.S. Food and Drug Administration (FDA) in connection with U.S. approval of VOXZOGO. Non-GAAP Income is defined by the Company as reported GAAP Net Income, excluding amortization expense, stock-based compensation expense, contingent consideration, and, in certain periods, certain other specified items. The Company also includes a Non-GAAP adjustment for the estimated income taxim pact of reconciling items. Refer to Non-GAAP Information on slide 11 of this presentation for reconciliations to the comparable information reported under U.S. GAAP. BIOMARIN

View entire presentation